Met Non Small Cell Cancer Registry (MOMENT)

Merck KGaA (EMD Serono)

Status: Enrolling

Conditions: Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT05376891

MS200095_0050

Details and patient eligibility

About

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.

The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.

Full description

This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

Enrollment: 700 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who signed ICF
• Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
• Participants who are starting or are already being treated with systemic therapy

Exclusion criteria

• Participants who are enrolled in a clinical trial

Trial design

700 participants in 1 patient group

Advanced Non-small Cell Lung Cancer with METex14 skipping alterations

Description:

Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.